Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Clinical trial NCT06744504 · RECRUITING
Trial details
- NCT number
- NCT06744504
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-10
- Primary completion
- 2027-12-01
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.